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Abstract
Elevated low-density lipoprotein (LDL)-cholesterol is associated with a significantly increased risk
of coronary heart disease. Ezetimibe is the first member of a new class of selective cholesterol
absorption inhibitors. It impairs the intestinal reabsorption of both dietary and hepatically excreted
biliary cholesterol. Ezetimibe is an effective and safe agent for lowering LDL-C and non HDL-C.
Short term clinical trials have established the role of ezetimibe monotherapy and its use in
combination with statins. Furthermore, ezetimibe and statin combination therapy increased the
percentage of patients who achieved their LDL-C treatment goal.
Studies using surrogate markers of atherosclerosis have suggested a possible role of ezetimibe in
combating atherosclerosis. Ezetimibe provides an effective therapeutic strategy for the
management of homozygous familial hypercholesterolemia (HoFH) and sitosterolemia. The lack of
outcomes and long term safety data is attributed to the relatively recent introduction of this
medication.
Background
Over 60 million Americans suffer from cardiovascular dis-
ease (CHD). The incidence of CHD and stroke has been
on the rise partly because of the increase in life expectancy
and the explosive epidemic of diabetes and the metabolic
syndrome [1]. CHD is responsible for about 38% of the
overall mortality in the United States making it the
number one killer of Americans [2].
Animal and human studies have established the role of
cholesterol in the development and progression of athero-
sclerosis. LDL-cholesterol (LDL-C) constitutes approxi-
mately 60–70 % of total serum cholesterol.
Epidemiological studies directly implicated LDL-C to the
development of atherosclerosis and CHD. Furthermore,
LDL-C level appears to be directly related to the develop-
ment and recurrence of CHD [3].
Animal studies suggested a protective effect of low LDL-C
against atherosclerosis [2]. Multiple human trials examin-
ing the relationship of LDL-C lowering in primary and
secondary prevention of CHD have demonstrated the
impact of reducing LDL-C levels on decreasing CHD and
CHD related mortality [4-8].
Published: 07 October 2004
Lipids in Health and Disease 2004, 3:22 doi:10.1186/1476-511X-3-22
Received: 23 September 2004
Accepted: 07 October 2004
This article is available from: http://www.lipidworld.com/content/3/1/22
© 2004 Al-Shaer et al; licensee BioMed Central Ltd. 
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Lipids in Health and Disease 2004, 3:22 http://www.lipidworld.com/content/3/1/22
Page 2 of 6
(page number not for citation purposes)
Most of the landmark CHD prevention trials involved the
use of statin medications. LDL-C remains the primary tar-
get of treatment in most instances, and statins are the
mainstay of LDL-C lowering treatment [9].
The National Cholesterol Education Program/ Adult
Treatment Panel III (NCEP/ATP III) updated guidelines
(table 1) for detection and treatment of dyslipidemia
envisioned LDL-C below 100 mg/dL to be optimal for all
patient risk categories. These more aggressive guidelines
resulted in doubling of the number of patients that are not
at target LDL-C levels as compared to previous guidelines
[2]. Recent NCEP/ATP III update data suggested even
lower LDL-C levels than previously advocated, making it
harder to achieve the treatment in many instances and rec-
ommended the use of combination therapy if needed to
help achieve the treatment targets. The NCEP/ATP III
update emphasized "the lower, the better" hypothesis
[10].
Cholesterol Absorption inhibitors
Ezetimibe, a cholesterol absorption inhibitor, is the first
agent of a new class of lipid-lowering compounds that
selectively inhibits the intestinal absorption of cholesterol
and related phytosterols. Ezetimibe undergoes extensive
glucuronidation to an active metabolite in the intestinal
mucosa [11]. Ezetimibe acts on brush border of the small
intestine and decreases biliary and dietary cholesterol
from the small intestine uptake into the enterocytes.
Ezetimibe is primarily metabolized in the small intestine
and liver via glucuronide conjugation with subsequent
biliary and renal excretion [12]. Ezetimibe does not affect
the absorption of fat-soluble vitamins, triglycerides, or
bile acids [13].
After oral administration, ezetimibe is absorbed and
extensively conjugated to a pharmacologically active phe-
nolic glucuronide (ezetimibe-glucuronide) [14], the drug
and its metabolite have a half-life of approximately 22
hours [8]. Concomitant food administration (high fat or
non-fat meals) had no effect on the extent of absorption
of ezetimibe when administered in the 10-mg clinical
dose [15]. Ezetimibe and ezetimibe-glucuronide are
highly bound (>90%) to human plasma proteins [16].
Plasma concentrations for total ezetimibe were about 2-
fold higher in older individuals (>65 years), levels were
similar in adolescents to healthy adults and may be higher
in women than in men [8]. In patients with severe renal
disease, ezetimibe level was increased approximately 1.5-
fold, compared to healthy controls [17]. Ezetimibe had no
significant effects on the bioavailability of warfarin, fenof-
ibrate, HMG CoA reductase inhibitors, or digoxin [16,18-
20].
Adverse experiences were reported in approximately 2%
of patients treated with ezetimibe and included fatigue,
arthralgia, diarrhea, abdominal pain and back pain.
Angioedema and rash were reported after general clinical
use of this medication [16]. With co-administration of
ezetimibe and statins the adverse event profile was similar
to that for statins alone. In a recently published case
report, the authors described two patients whose creati-
nine kinase (CK) increased after the addition of ezetimibe
to statin therapy causing one of the patients to experience
myalgia and tendinopathy. This finding raises the ques-
tion of whether ezetimibe can be implicated in precipitat-
ing increased risk of stain-associated myopathy [21].
The Role of Ezetimibe in Clinical Practice
Indications for use
1. Primary Hypercholesterolemia (heterozygous familial
and non-familial), Ezetimibe is indicated in this case for
use as both mono and combination therapy.
2. The reduction of elevated total-C and LDL-C levels in
patients with homozygous familial hypercholesterolemia
(HoFH) either as primary or as an adjunct to other lipid-
lowering treatments.
3. In patients suffering from Homozygous Sitosterolemia,
as adjunctive therapy to diet for the reduction of elevated
Table 1: Synopsis of the updated ATP III LDL-C Goals and Cut-points for TLC and Drug Therapy in Different Risk Categories and 
Proposed Modifications Based on Recent Clinical Trial Evidence
Risk Category Goal TLC Drug Therapy
High risk: CHD or CHD risk 
equivalents (10-year risk >20%)
< 100 mg/dL 
(optional goal: <70 mg/dL)
≥ 100 mg/dL ≥ 100 (<100 mg/dL: consider drug options)
Moderately high risk: 2+ risk factors 
(10-year risk 10% to 20%)
< 130 mg/dL ≥ 130 mg/dL ≥ 130 mg/dL(100–129 mg/dL; consider drug options)
Moderate risk: 2+ risk factors 
(10-year risk <10%)
< 130 mg/dL ≥ 130 mg/dL ≥ 160 mg/dL
Lower risk: 0–1 risk factor < 160 mg/dL ≥ 160 mg/dL ≥ 190 mg/dL (160–189 mg/dL: LDL-lowering drug optional)Lipids in Health and Disease 2004, 3:22 http://www.lipidworld.com/content/3/1/22
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sitosterol and campesterol levels in patients with
homozygous familial sitosterolemia.
Monotherapy
Multiple studies conducted to examine the effects of
ezetimibe monotherapy have concluded that this drug
was effective in lowering LDL-C versus placebo.
Analysis of multicenter, double-blind, placebo-controlled
trials demonstrated that ezetimibe at the 10 mg once daily
clinically approved dose significantly modified choles-
terol and cholesterol subtypes in patients with hypercho-
lesterolemia when compared to placebo. Ezetimibe
significantly lowered total-Cholesterol (TC) (12 %), LDL-
C (18 %), apolipoprotein B (Apo B) (15 %), and triglyc-
erides (TG) (7%) and increased high density lipoprotein
(HDL-C) (3.5%) [22-24]. Lipoprotein (a) [Lp (a)] was not
significantly affected by Ezetimibe 10 mg once a day treat-
ment [25].
In a case series report, we analyzed the effects of Ezetimibe
on cholesterol particle size and number using NMR tech-
nology (Lipo science, Raleigh, NC). We found that
Ezetimibe lowered cholesterol particle number by a mean
26 % and had no significant effect on cholesterol particle
size [26].
The effects of ezetimibe on cholesterol and its subtypes
were not influenced by risk-factor status, gender, age, race,
time of administration, or baseline lipid profile [22]. The
overall incidence of adverse effects with ezetimibe mono-
therapy was similar to placebo.
Combination therapy
The struggle to achieve the NCEP/ATP III guidelines LDL-
C goals through primary utilization of statins is often frus-
trating for the clinician. In a study to examine the efficacy
of statin titration on attainment of LDL-C goal, the
authors concluded that for high risk patients, approxi-
mately half were able to achieve their LDL-C goal at the
appropriate statin starting dose, and only one third of the
titration group were able to achieve the NCEP/ATP III cho-
lesterol goal [27]. Now with the very recent publication of
the update to the NCEP/ATP III, clinicians are faced with
even lower goals of LDL-C, Making combination therapy
a must in more cases than previously advocated by the
NCEP/ATP III [10].
HMG-CoA reductase inhibitors (statins) act on the rate-
limiting step to inhibit HMG-CoA conversion to meval-
onate, effectively decreasing LDL-C synthesis. They result
in a decrease of LDL-C ranging between 30–60 %,
depending on the individual statin and the dose adminis-
tered. Statin induced LDL-C lowering appears to be effec-
tive in reducing CHD and CHD related mortality and
morbidity. The extent of CHD and CHD related events
reduction is proportionate to the extent of LDL-C reduc-
tion [10,28]. LDL-C reduction trials have demonstrated a
reduction in CHD related events by approximately 20–
40% [4-8].
Reasons to initiate combination therapy to treat hyperlip-
idemia include: further LDL-C lowering, reducing side
effects related to higher doses of statins, modifying other
risk factors besides LDL-C such as HDL-C and TG.
Increasing the dose of statins has a limited effect on reduc-
ing LDL-C, as it is well established that doubling the dose
of a statins leads to a 5 % more reduction in total TC and
7 % more reduction in LDL-C with each doubling [29].
Although statins have demonstrated similarity in CHD
related events, they are heterogeneous not only in LDL-C
lowering efficacy but also in their safety profiles. The bulk
of the statins effect on LDL-C occurs at the initial recom-
mended dose and they are safer when used at doses below
the maximal recommended dose.
Statins are the most effective drugs known to modify LDL-
C, but in terms of HDL-C and TG modifying capacity,
other classes of lipid lowering medications used alone or
in combination with statins offer higher efficacy.
The metabolism of cholesterol is an intricate process that
involves both produced and ingested cholesterol. The
mechanism of action of HMG-CoA reductase inhibitors
affects the production of cholesterol, whereas that of cho-
lesterol absorption inhibitors affects absorbed choles-
terol, thereby offering potential synergism of action when
the medication are used in combination. Trials examining
the efficacy have demonstrated synergism and consistency
in LDL-C lowering in the absence pharmacokinetic inter-
action between the statins and ezetimibe.
In a relatively large, multicenter study, involving patients
with primary hypercholesterolemia already receiving sta-
tin monotherapy (but who had not met their NCEP ATP
II target LDL-C goal), patients were randomized to receive
either ezetimibe or placebo in addition to their current
statin therapy. At the conclusion of this 8 week study, the
ezetimibe and statin groups were found to have a signifi-
cantly lower total-C, LDL-C, Apo B, and TG, and increased
HDL-C when compared to the statin only and placebo
groups. Furthermore, LDL-C reductions induced by
ezetimibe were generally consistent across all statins
groups [30].
Another multicenter, double-blind, randomized trial
examined the effects of ezetimibe on patients suffering
from (HoFH). At the initiation of the trial patients wereLipids in Health and Disease 2004, 3:22 http://www.lipidworld.com/content/3/1/22
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receiving either atorvastatin or simvastatin. The addition
of ezetimibe reduced LDL-C by an additional 20.5 % in
contrast to only 6.7 % reduction that resulted from dou-
bling the statin dose [31]. Similar results were demon-
strated in high-risk patients with familial heterozygous
hypercholesterolemia (HeFH) [32].
The addition of ezetimibe to statins is superior to treat-
ment with statins alone in lowering non-HDL-C,
ezetimibe co-administered with simvastatin lowered non-
HDL-C by 47.1% whereas, simvastatin monotherapy low-
ered non-HDL-C by 33.6% when results were pooled
across different doses [33].
In terms of modifying risk factors other than LDL-C, the
co-administration of ezetimibe with statins had a more
favorable effect on HDL-C and TG when compared to stat-
ins therapy alone [33]. In conclusion, the addition of
ezetimibe to statins produced further lowering of LDL-C
of approximately 15–20 % with no apparent increase in
side effects. This effect was superior to that observed by
doubling the dose of the statins. Furthermore, the lower-
ing produced was consistent.
Ezetimibe co-administration with fibric acid derivatives
was examined in a randomized, evaluator-blind, placebo-
controlled, parallel-group study of 32 healthy hypereho-
lesterolemics. Ezetimibe co-administration with fenofi-
brate was found to produce clinically significant
reductions in LDL-C (36.3%) compared to the fenofibrate
group (22.3%) with a more favorable TG and HDL-C pro-
file [34].
Sitosterolemia
Sitosterolemia is a rare inherited disorder caused by muta-
tion in either the ABCG5 or ABCG8 genes located on chro-
mosome (2p21) [35]. First described by Bhattacharyya
and Connor in 1974 in two sisters of German and Ger-
man-Swiss ancestry with normal mental development.
The patients presented with tendinous and tuberous xan-
thoma and elevation of beta-sitosterol, campesterol and
stigmasterol (plant sterols) in the blood [36]. Affected
individuals have increased intestinal absorption of plant
sterols (mainly sitosterol) that are usually absorbed in
minute amounts in normal individuals. Additionally,
these patients have diminished clearance of plant sterols,
leading to very high levels of plant sterols in the plasma.
Patients suffering from sitosterolemia have severely
depressed hepatic cholesterol biosynthesis, and decreased
levels of HMG-CoA reductase enzyme [37].
Clinical manifestations include: tendon and tuberous
xanthomas, episodes of hemolysis, accelerated atheroscle-
rosis, and premature coronary artery disease. It is impor-
tant to note that close to 50 % of these patients have
normal cholesterol levels [38-41].
A recently reported trial demonstrated that treatment with
ezetimibe reduces plant sterol levels in patients with sito-
sterolemia. The authors reported a decrease in sitosterol
concentrations by 21% and campesterol by 24 % [42].
Ezetimibe and atherosclerosis
It is generally accepted that atherosclerosis is an inflam-
matory disorder. It is believed that the atherosclerotic
process begins with endothelial cell activation, which is
triggered by multiple factors such as oxidized lipopro-
teins. Cholesterol lowering agents as a group have demon-
strated great efficacy in prevention and cessation of the
progression of atherosclerosis. The efficacy of ezetimibe in
monotherapy or in combination on CHD morbidity and
mortality has not been well established.
One of the unique features of cholesterol absorption
inhibitors is their ability to modify post-prandial hyperli-
pidemia. There is increasing evidence that post-prandial
lipoproteins (particularly cholesterol-rich chylomicron
remnant) are atherogenic. Ezetimibe has the potential to
reduce the cholesterol content of chylomicrons by up to
60% [44], which may lead to a lower atherogenic poten-
tial of chylomicron remnants [43].
High-sensitivity C-reactive protein (hs-CRP) is an inflam-
matory mediator whose levels correlate with increased
coronary risk. Ezetimibe co-administered with simvasta-
tin resulted in significant incremental decreases in hs-CRP
in patients with primary hypercholesterolemia. Changes
in individual lipid parameters did not explain the
observed decreases in hs-CRP and were possibly consist-
ent with an additional anti-inflammatory effect compared
with simvastatin monotherapy [45].
In a prospective trial to study effects of ezetimibe co-
administered with atorvastatin in patients with primary
hypercholesterolemia, ezetimibe plus atorvastatin signifi-
cantly provided an additional (10%) lowering of hs-CRP
versus atorvastatin alone [46].
The unanswered questions
Ezetimibe and its class of cholesterol absorption inhibi-
tors are new, and there is a lack of outcomes data to
explore whether its cholesterol modifying effects will
translate to lower CHD mortality and morbidity. The
safety of this medication has not yet been established with
long term trials data as most of the studies conducted were
short term. With the advent and increased utilization of
combination therapy in the management of dyslipidemia,
further trials are needed to explore the efficacy, indica-
tions and safety profile of ezetimibe use in combinationLipids in Health and Disease 2004, 3:22 http://www.lipidworld.com/content/3/1/22
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with Peroxisome proliferator-activated receptors (PPARs),
niacin and bile acid resins.
The increased popularity of special weight loss diets such
as the high protein diet, poses questions of whether such
diets will alter the efficacy or safety of cholesterol absorp-
tion inhibitors.
Finally, the efficacy of statins in reducing CHD related
events has lead to the controversial hypothesis regarding
whether or not statins poses a pleiotropic (non lipopro-
tein) effect. If a pleiotropic effect exists, one might argue
that a statin at a higher dose might be more beneficial
than combination therapy producing the same effect.
Conclusions
Ezetimibe is the first clinically approved cholesterol
absorption inhibitor. It is effective in lowering LDL-C as
monotherapy or in combination with statins. The use of
combination LDL-C lowering medication is expected to
become a much more common modality of treatment,
especially after the recent NCEP/ATP III update. Ezetimibe
offers further lowering of LDL-C and non HDL-C that is
consistent and probably safer than increasing the dose of
the individual statin. It also provides another effective
treatment option for HoFH and sitosterolemia patients.
Because of its recent introduction, we still lack both out-
comes and long term safety data.
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